{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:08:51Z","timestamp":1787843331738,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04226-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:45:43Z","timestamp":1751373943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An atypical cause of amyloidosis: a case of combined heavy and light chain amyloidosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Dina R.","family":"Gonzalez-Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Hanouneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Elena","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"4226_CR1","unstructured":"Tapia C, Bashir K, StatPearls. 2023. Nephrotic Syndrome. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470444\/"},{"issue":"4","key":"4226_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","volume":"31","author":"JN Buxbaum","year":"2024","unstructured":"Buxbaum JN, Eisenberg DS, F\u00e4ndrich M, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2024;31(4):249\u201356.","journal-title":"Amyloid"},{"key":"4226_CR3","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2215\/CJN.10491012","volume":"8","author":"SM Said","year":"2013","unstructured":"Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol. 2013;8:1515\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4226_CR4","doi-asserted-by":"crossref","unstructured":"Cervantes CE, Atta MG. Kidney amyloidosis: updates on pathogenesis and therapeutic frontiers. Am J Nephrol 2024;1\u201312.","DOI":"10.1159\/000539596"},{"issue":"Supplement 1","key":"4226_CR5","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2024-200911","volume":"144","author":"KY Li","year":"2024","unstructured":"Li KY, Staron A, Sanchorawala V, et al. Clinical characteristics and therapeutic response of patients with heavy chain (AH) and heavy and light chain (AHL) amyloidosis. Blood. 2024;144(Supplement 1):3303.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4226_CR6","doi-asserted-by":"publisher","first-page":"8092","DOI":"10.1182\/blood-2022-164617","volume":"140","author":"MS Ebraheem","year":"2022","unstructured":"Ebraheem MS, Muchtar E, Kumar SK, et al. Immunoglobulin heavy chain amyloidosis: patient characteristics and outcomes. Blood. 2022;140(Supplement 1):8092\u20133.","journal-title":"Blood"},{"issue":"3","key":"4226_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ki.2012.414","volume":"83","author":"SH Nasr","year":"2013","unstructured":"Nasr SH, Said SM, Valeri AM, et al. The diagnosis and characteristics of renal heavy chain and heavy\/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013;83(3):463\u201370.","journal-title":"Kidney Int"},{"issue":"12","key":"4226_CR8","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1093\/ndt\/gfh503","volume":"19","author":"L Novak","year":"2004","unstructured":"Novak L, Cook WJ, Herrera GA, et al. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transpl. 2004;19(12):3050\u20133.","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"4226_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.kint.2022.10.028","volume":"103","author":"S Karam","year":"2023","unstructured":"Karam S, Haidous M, Royal V, et al. Renal AA amyloidosis: presentation, diagnosis, and current therapeutic options: a review. Kidney Int. 2023;103(3):473\u201384.","journal-title":"Kidney Int"},{"issue":"6","key":"4226_CR10","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.ekir.2018.07.008","volume":"3","author":"SH Nasr","year":"2018","unstructured":"Nasr SH, Fidler ME, Said SM. Paraffin immunofluorescence: A valuable ancillary technique in renal pathology. Kidney Int Rep. 2018;3(6):1260\u20136.","journal-title":"Kidney Int Rep"},{"issue":"22","key":"4226_CR11","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1182\/blood-2013-04-494849","volume":"121","author":"SP Treon","year":"2013","unstructured":"Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood. 2013;121(22):4434\u20136.","journal-title":"Blood"},{"key":"4226_CR12","doi-asserted-by":"crossref","unstructured":"Otaka Y, Nakazato Y, Tsutsui T et al. Cardiac involvement in heavy and light chain amyloidosis: A case report and literature review. Med (Baltim). 2019;98(46).","DOI":"10.1097\/MD.0000000000017999"},{"key":"4226_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","volume":"20","author":"M Grogan","year":"2015","unstructured":"Grogan M, Dispenzieri A. Natural history and therapy of AL cardiac amyloidosis. Heart Fail Rev. 2015;20:155\u201362.","journal-title":"Heart Fail Rev"},{"key":"4226_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ahj.2012.04.013","volume":"164","author":"J Dungu","year":"2012","unstructured":"Dungu J, Sattianayagam PT, Whelan CJ, et al. The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in AfroCaribbean patients. Am Heart J. 2012;164:72\u20139.","journal-title":"Am Heart J"},{"issue":"1","key":"4226_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12872-021-01856-3","volume":"21","author":"C Lei","year":"2021","unstructured":"Lei C, Zhu X, Hsi DH, et al. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters. BMC Cardiovasc Disord. 2021;21(1):43.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"4226_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaccao.2022.08.007","volume":"4","author":"A Cipriani","year":"2022","unstructured":"Cipriani A, De Michieli L, Porcari A, et al. Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value. JACC CardioOncol. 2022;4(4):458\u201370.","journal-title":"JACC CardioOncol"},{"issue":"18","key":"4226_CR17","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.3390\/jcm13185588","volume":"13","author":"L Teresi","year":"2024","unstructured":"Teresi L, Trimarchi G, Liotta P, et al. Electrocardiographic patterns and arrhythmias in cardiac amyloidosis: from diagnosis to therapeutic Management-A narrative review. J Clin Med. 2024;13(18):5588.","journal-title":"J Clin Med"},{"issue":"15","key":"4226_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325\u201332.","journal-title":"Blood"},{"issue":"2","key":"4226_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5045\/br.2022.2021227","volume":"57","author":"BZ Maroun","year":"2022","unstructured":"Maroun BZ, Allam S, Chaulagain CP. Multidisciplinary supportive care in systemic light chain amyloidosis. Blood Res. 2022;57(2):106\u201316.","journal-title":"Blood Res"},{"key":"4226_CR20","doi-asserted-by":"publisher","first-page":"907584","DOI":"10.3389\/fonc.2022.907584","volume":"12","author":"CE Jensen","year":"2022","unstructured":"Jensen CE, Byku M, Hladik GA, et al. Supportive care and symptom management for patients with Immunoglobulin light chain (AL) amyloidosis. Front Oncol. 2022;12:907584.","journal-title":"Front Oncol"},{"key":"4226_CR21","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.hoc.2020.08.007","volume":"34","author":"SW Wong","year":"2020","unstructured":"Wong SW, Fogaren T. Supportive care for patients with systemic light chain amyloidosis. Hematol Oncol Clin North Am. 2020;34:1177\u201391.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4226_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1200\/OP.22.00396","volume":"19","author":"D Dima","year":"2023","unstructured":"Dima D, Mazzoni S, Anwer F, et al. Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation. JCO Oncol Pract. 2023;19:265\u201375.","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"4226_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","volume":"95","author":"A Angel-Korman","year":"2019","unstructured":"Angel-Korman A, Stern L, Sarosiek S, et al. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019;95(2):405\u201311.","journal-title":"Kidney Int"},{"issue":"10","key":"4226_CR24","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/TP.0000000000003170","volume":"104","author":"A Angel-Korman","year":"2020","unstructured":"Angel-Korman A, Havasi A. Kidney transplantation in systemic amyloidosis. Transplantation. 2020;104(10):2035\u2013204.","journal-title":"Transplantation"},{"key":"4226_CR25","doi-asserted-by":"crossref","unstructured":"Anand SK, Sanchorawala V, Verma A. Systemic Amyloidosis and Kidney Transplantation: An Update. Semin Nephrol. 2024;44(1):151496.","DOI":"10.1016\/j.semnephrol.2024.151496"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04226-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:03:55Z","timestamp":1751414635000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04226-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04226-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mohamad Hanouneh reports serving on a speaker\u2019s bureau for AstraZeneca, Bayer, Alexion, Novartis, and Boehringer Ingelheim. The remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}